Novel licensure pathways for expeditious introduction of new tuberculosis vaccines: a discussion of the adaptive licensure concept.

[1]  M. Brennan,et al.  Preventive vaccines for tuberculosis. , 2013, Vaccine.

[2]  K. Cichutek,et al.  A global regulatory science agenda for vaccines. , 2013, Vaccine.

[3]  Peter Høngaard Andersen,et al.  Priorities for improving drug research, development and regulation , 2013, Nature Reviews Drug Discovery.

[4]  S. Self,et al.  Designing an adaptive phase II/III trial to evaluate efficacy, safety and immune correlates of new TB vaccines in young adults and adolescents. , 2013, Tuberculosis.

[5]  H. Eichler,et al.  Adaptive Licensing: Taking the Next Step in the Evolution of Drug Approval , 2012, Clinical pharmacology and therapeutics.

[6]  M. Brennan,et al.  Tuberculosis vaccines: a strategic blueprint for the next decade. , 2012, Tuberculosis.

[7]  Nathalie Strub-Wourgaft,et al.  Registering New Drugs for Low-Income Countries: The African Challenge , 2011, PLoS medicine.

[8]  Diadié Maïga,et al.  Regulatory oversight of clinical trials in Africa: progress over the past 5 years. , 2009, Vaccine.

[9]  M. Brennan.  The US Food and Drug Administration Provides a Pathway for Licensing Vaccines for Global Diseases , 2009, PLoS medicine.

[10]  M. Brennan,et al.  Development of New Tuberculosis Vaccines: A Global Perspective on Regulatory Issues , 2007, PLoS medicine.

[11]  R. Katz,et al.  Biomarkers and surrogate markers: An FDA perspective , 2004, NeuroRX.

[12]  Richard Pazdur,et al.  End points and United States Food and Drug Administration approval of oncology drugs. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Ramsay,et al.  Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. , 2001, Vaccine.

[14]  P. Escalante.  Tuberculosis , 1904, Annals of Internal Medicine.